Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606144 | 0.89 | SMN1; SMN2 (0.56) | CASP1SMN1; SMN2 | |
| SCHEMBL3305290 | 0.89 | SMN1; SMN2 (0.56) | CASP1SMN1; SMN2 | |
| SCHEMBL3263207 | 0.86 | SMN1; SMN2 (0.48) | CASP1SMN1; SMN2 | |
| SCHEMBL10888856 | 0.85 | CASP1 (0.59) | CASP1 | |
| SCHEMBL10884952 | 0.85 | CASP1 (0.59) | CASP1 | |
| SCHEMBL1235161 | 0.83 | CTSK (0.49) | — | |
| SCHEMBL1235160 | 0.83 | CTSK (0.49) | — | |
| SCHEMBL4279525 | 0.83 | CTSK (0.49) | — | |
| SCHEMBL6276993 | 0.83 | SMN1; SMN2 (0.47) | CASP1SMN1; SMN2 | |
| SCHEMBL6276996 | 0.83 | SMN1; SMN2 (0.47) | CASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209822-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2004-10-21 | — | — | US | disclosed |
| US-20030207923-A1 | 2,'3-Amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-11-06 | — | — | US | disclosed |
| EP-1242367-A1 | 2-[3-AMINO-4-(N-HYDROXYAMINO)-SUCCINYLAMINO-ACETAMIDES FOR USE AS CD23 FORMATION INHIBITORS | SmithKline Beecham plc (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049657-A1 | 2-`3-AMINO-4-(N-HYDROXYAMINO)-SUCCINYLAMINO-ACETAMIDES FOR USE AS CD23 FORMATION INHIBITORS | SMITHKLINE BEECHAM, PLC (GB) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207923-A1 | 2,'3-Amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors | CD2, CD22, NEU3 | CASP1 1540/4885SMN1; SMN2 544/4885 |
| US-20040209822-A1 | Novel compounds | CD2, CD22, SSB | CASP1 428/4885SMN1; SMN2 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.